CAROLINE N MBOGUA, MD

Internal Medicine Specialist & Pediatrics
cmbogua@synergygroupus.com

AFFILIATED ADDRESSES

Synergy Groups Medical LLC
8121 Broadway Street, Suite 120/111 Houston, TX 77061
3281 Rocky Creek Dr. Ste. 500 Missouri City, TX 77459
10101 Bissonnet #105 A-C, Houston, TX 77036

21 Mar 2024

EDUCATION

Residency-Internal Medicine – 1992
Baylor College of Medicine, TX – USA

Residency - Pediatrics – 1990
Baylor College of Medicine, TX – USA

Doctor of Medicine - 1987
Howard University of College of Medicine, Washington.- USA

Bachelor of Science - 1983
Pennsylvania State University, PA – USA

LICENSE

1. Medical License, State of Texas- #J0775
2. Drug Enforcement Agency – Registration # FM6939182
3. NPI#1942221148

BOARD CERTIFICATION

- American Board of Pediatrics – since 1993
  - Board Eligible – since 2013
- American Board of Internal Medicine - since 1992

TRAINING/CERTIFICATIONS

- Collaborative Institutional Training Initiative (CITI) Good Clinical Practice : (Current)
- The National Institutes of Health (NIH): Completed 01Aug2018
- EDC(Current)
- Virtual Trial Capable Certified (Current)

LANGUAGE

1. Fluent in English
2. Fluent in Spanish

EXPERIENCE

Principal/Sub-Investigator 2016-Present
Synergy Groups Medical LLC
(Previously Known as **Discovery MM Services, Inc.**)

Principal/Sub-Investigator 2009-2016
Gulf Coast Medical Research, TX

Physician 2016-Present
VCare Clinics - Houston, TX

Solo Practice 1994-2014
Caroline Mbogua, MD – Houston, TX

Staff Physician 1998-1999
TENET Health Center, TX

RESEARCH:

- A 52 Week, Phase III double-blind, Randomize, Placebo-controlled, and Parallel- Group Study to Assess the Efficacy, Safety and Tolerability of XXXX in Subjects with Primary Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Event
- An open Label, Randomized, Parallel- group, three treatment arm, multicenter study on Hypogonadal males to evaluate the effect on 24-hour ambulatory blood pressure after 16-week continuous treatment with marketed testosterone products
- Efficacy and safety of GMRx2 (a single pill combination containing telmisartan/amlodipine/ indapamide) compared to placebo for the treatment of hypertension: An international, multi center, randomized, double-blind, placebo controlled, parallel group trial
- A randomized, multicenter, open-label trial comparing the effectiveness of an "inclisiran first" implementation strategy to usual care on LDL cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease and elevated LDL-C (>70 mg/dl) despite receiving maximally tolerated statin therapy(VICTORION- INITIATE)
- A Trial Comparing Cardiovascular Safety of Insulin XXXX versus Insulin XXX in Subjects with type 2 Diabetes at high risk of cardiovascular events

- A National, Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of XXXX (X and X mg) in Patients with Chronic Idiopathic Constipation
- Principal Investigator- A Phase II, 16-week, double-blind, placebo-controlled, parallel-group, randomized, multicenter trial to assess effect on glycemic control of three doses of XXXX in subjects with inadequately controlled type 2 diabetes receiving a stable dose of metformin
- A Phase III, Randomized, Double-blind, Active-Controlled, Parallel-Group Study of the Comparative Efficacy and Safety of XXXX in Subjects with Acute Otitis External
- Randomized, double-blind, placebo-controlled Phase IIB study on safety and therapeutic efficacy of XXXX in adult subjects with naturally acquired influenza
- Study of XXXX to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
- Principal Investigator- Randomized, double-blind, placebo-controlled Phase III study to evaluate the long-term efficacy and safety of Study Drug Inhalation powder XXX versus placebo when administered via the Novel Dry Powder Inhaler once daily in subjects with moderate COPD and a history of, or at increased risk for cardiovascular disease - 2012
- A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin XXX XX U/Ml vsInsulin XXX in Subjects with Type 2 Diabetes Mellitus Requiring High-dose Insulin
- The Efficacy of Insulin XXX/XXX in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy
- The Efficacy of Insulin XXX/XXX as add-on Therapy in Controlling Glycaemia in Adults with Type 2 Diabetes Inadequately Controlled on Sulphonylurea with or Without Metformin Therapy
- A 24-week, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of Toujeo® and Tresiba® in Insulin-Naive Patients with Type 2 Diabetes Mellitus not Adequately Controlled with Oral Antidiabetic Drug(s) ± GLP-1 receptor agonist
- A 26 Week randomized, open-label, active controlled, parallel-group, study assessing the efficacy and safety of the insulin XXX/XXX fixed ratio combination in adults with type 2 diabetes inadequately controlled on GLP-1 receptor agonist and metformin ± pioglitazone, followed by a fixed ratio combination single-arm 26 week extension period
- Efficacy in controlling glycaemia with XXXX as add-on metformin vs. OAD's as add-on to metformin after up to 104 weeks of treatment in subjects with type 2 diabetes inadequately controlled with metformin monotherapy and treated in a primary care setting
- Phase III randomized, 12 weeks, double-blind, placebo-controlled study of the safety and efficacy of XXX in patients with irritable bowel syndrome with constipation (IBS-C)
- An open-label, long-term safety and tolerability study of XXX in patients with irritable bowel syndrome with constipation (IBS-C)
- A randomized, double-blind, placebo-controlled, parallel-group, multicenter event driven

Phase III study to investigate the efficacy and safety of XXX, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnose in subjects with type 2 diabetes mellitus and the clintal diagnosis of diabetic kidney

- A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of XXX on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease
- A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase 3 study to investigate the efficacy and safety of XXX on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care

- Phase II, A Study on Efficacy and Safety of XXX in the treatment of patients with Obesity.
- Phase III, A Safety and Efficacy Study of XXXX to Evaluate the Long-Term Treatment of Obesity in Adults with Obesity-Related Co-Morbid Conditions.
- A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of XXXXX compared to Empagliflozin, and Placebo in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
- A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of XXX on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function
- An International Phase III, Randomized, Double-Blind, Placebo- and Active (XXX)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of XXX in Patients with Symptoms of Overactive Bladder
- An International Phase III, Randomized, Double-Blind, Active (XXX)-Controlled Multicenter Extension Study to Evaluate the Long-Term Safety and Efficacy of XXX in Patients with Symptoms of Overactive Bladder
- Testosterone Replacement therapy for Assessment of long-Term Vascular Events and efficacy Response in hypogonadal Men (TRAVERSE) Study Phase: IV
- A Phase IV Study of the Clinical and Microbiologic Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection in Adult Women
- Evaluation of XXX ER XX and XX mg Efficacy and Safety in Children with ADHD - A Double-Blind, Placebo Controlled, Pivotal Trial
- Evaluation of XXXX ER XX and XX mg Efficacy and Safety in Adolescents with ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial
- Getting to an improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia

management (GOULD): registry of High Cardiovascular Risk Subjects in the United States.

- Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of XXXX ER for the Treatment of Pediatric Patients with Attention Deficit/Hyperactivity Disorder (ADHD).
- A double-blind, randomized, placebo-controlled, parallel group trial to evaluate the efficacy and safety of XXX and XXX over 26 weeks, with a double-blind active treatment safety extension period up to 52 weeks, in children and adolescents with type 2 diabetes mellitus. (XXX)
- A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of XXXX in Adults and Adolescents with Severe Uncontrolled Asthma (NAVIGATOR)
- Phase IIB/III double-blinded placebo-controlled efficacy trial of XXXX gel for the prevention of acquisition of urogenital Chlamydia trachomatis infection

- A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel-group Study of the Efficacy and Safety of XXXX in Children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C)
- Assessment of Efficacy and Safety of XXX-XXX for the Treatment of Impulsive Aggression (IA) in Adolescent Subjects with Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction with Standard ADHD Treatment
- A Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel dose Cohort study to evaluate the efficacy and safety of twelve once-weekly subcutaneous doses of XX-XXX to patients with type 2 diabetes mellitus (T2DM) not well-controlled by Metformin monotherapy
- A Randomized, Double-Blinded, Adaptive Phase II Study to Evaluate the Safety and Efficacy of Oral XXXX and OralXXXX in the Treatment of Female Adults with Cystitis
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of XXXX 4 g Extended-Release Granules (Sachet) for the Induction of Clinical and Endoscopic Remission in Active, Mild to Moderate Ulcerative Colitis
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Tacrolimus Ointment
- A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of XXXXXX to XXXXXX in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
- A randomized, sham controlled, double-blind, multi-center study of Neuromuscular Electrical Stimulation (NMES) as an Adjunctive Therapy for Knee Pain Relief and Improving Functional Outcomes in Knee Osteoarthritis (OA) Patients

- A Randomized, Multicenter, Double-blind, Double-dummy, Parallel-group, Placebo and Active Comparator-controlled, Dose Finding, and Phase II Study to Assess Efficacy and Safety of XXXXXX in Gout Patients with Hyperuricemia
- A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral XXXX in Mild to Moderate Ulcerative Colitis
- A Double-Blind, Placebo-Controlled, Phase II, Responsive Adaptive Randomization Study of XXXX in Patients with Irritable Bowel Syndrome with Diarrhea (IBS-D)
- A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of XXXX Administered Orally to Children, Ages 6 to 17 Years, With Functional Constipation (FC)
- Open-Label Extension Study to Evaluate the Long-Term Safety of XXXXX Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric and Adolescent Subjects with Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction with Standard ADHD treatment
- A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of XXXX for the Management of Hyperkalemia in Subjects Receiving Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Medications for the Treatment of Heart Failure (DIAMOND)
- A Phase II Randomized, Double Blind, Placebo-Controlled, Parallel Group, Multicenter Study To Evaluate The Safety And Efficacy Of Repeated Oral Doses Of XXXX™ In Adult Subjects With Irritable Bowel Syndrome (Ibs) Subtypes Ibs-C And Ibs-D
- Assessment of Efficacy and Safety of SPN-810 for the Treatment of Impulsive Aggression (IA) in Adolescent Subjects with Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction with Standard ADHD Treatment
- A Phase III double-blind placebo-controlled efficacy trial of XXXXXX vaginal gel for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection
- An observational study to compare human saliva samples to nasopharyngeal swab specimens for COVID-19 detection
- A population based epidemiological XXXXX/XXXX registry and research project
- A 52-week, Phase III double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of pf-xxxxxx in subjects with primary hyperlipidemia or mixed dyslipidemia at risk of cardiovascular events